395 related articles for article (PubMed ID: 26805040)
1. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.
Edwards JL; Jennings MP; Apicella MA; Seib KL
Crit Rev Microbiol; 2016 Nov; 42(6):928-41. PubMed ID: 26805040
[TBL] [Abstract][Full Text] [Related]
2. Progress Toward a Gonococcal Vaccine: The Way Forward.
Russell MW; Jerse AE; Gray-Owen SD
Front Immunol; 2019; 10():2417. PubMed ID: 31681305
[TBL] [Abstract][Full Text] [Related]
3. Biological feasibility and importance of a gonorrhea vaccine for global public health.
Vincent LR; Jerse AE
Vaccine; 2019 Nov; 37(50):7419-7426. PubMed ID: 29680200
[TBL] [Abstract][Full Text] [Related]
4. Neisseria gonorrhoeae vaccine development: hope on the horizon?
Edwards JL; Jennings MP; Seib KL
Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates.
Baarda BI; Zielke RA; Holm AK; Sikora AE
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536323
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.
Gulati S; Pennington MW; Czerwinski A; Carter D; Zheng B; Nowak NA; DeOliveira RB; Shaughnessy J; Reed GW; Ram S; Rice PA
mBio; 2019 Nov; 10(6):. PubMed ID: 31690678
[TBL] [Abstract][Full Text] [Related]
7. Biology of the Gonococcus: Disease and Pathogenesis.
Shaughnessy J; Ram S; Rice PA
Methods Mol Biol; 2019; 1997():1-27. PubMed ID: 31119614
[TBL] [Abstract][Full Text] [Related]
8. The potential impact of vaccination on the prevalence of gonorrhea.
Craig AP; Gray RT; Edwards JL; Apicella MA; Jennings MP; Wilson DP; Seib KL
Vaccine; 2015 Aug; 33(36):4520-4525. PubMed ID: 26192351
[TBL] [Abstract][Full Text] [Related]
9. Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development.
Rice PA; Shafer WM; Ram S; Jerse AE
Annu Rev Microbiol; 2017 Sep; 71():665-686. PubMed ID: 28886683
[TBL] [Abstract][Full Text] [Related]
10. Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection.
Parzych EM; Gulati S; Zheng B; Bah MA; Elliott STC; Chu JD; Nowak N; Reed GW; Beurskens FJ; Schuurman J; Rice PA; Weiner DB; Ram S
mBio; 2021 Mar; 12(2):. PubMed ID: 33727348
[TBL] [Abstract][Full Text] [Related]
11. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
12. The Lst Sialyltransferase of Neisseria gonorrhoeae Can Transfer Keto-Deoxyoctanoate as the Terminal Sugar of Lipooligosaccharide: a Glyco-Achilles Heel That Provides a New Strategy for Vaccines to Prevent Gonorrhea.
Jen FE; Ketterer MR; Semchenko EA; Day CJ; Seib KL; Apicella MA; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33758087
[TBL] [Abstract][Full Text] [Related]
13. Vaccine research for gonococcal infections: where are we?
Jerse AE; Deal CD
Sex Transm Infect; 2013 Dec; 89 Suppl 4():iv63-8. PubMed ID: 24243883
[TBL] [Abstract][Full Text] [Related]
14. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
Semchenko EA; Tan A; Borrow R; Seib KL
Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148
[TBL] [Abstract][Full Text] [Related]
15. Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap.
Gottlieb SL; Jerse AE; Delany-Moretlwe S; Deal C; Giersing BK
Sex Health; 2019 Sep; 16(5):426-432. PubMed ID: 31476278
[TBL] [Abstract][Full Text] [Related]
16. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
[TBL] [Abstract][Full Text] [Related]
17. Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea.
Zielke RA; Wierzbicki IH; Baarda BI; Gafken PR; Soge OO; Holmes KK; Jerse AE; Unemo M; Sikora AE
Mol Cell Proteomics; 2016 Jul; 15(7):2338-55. PubMed ID: 27141096
[TBL] [Abstract][Full Text] [Related]
18. Potent
Edwards JL; Balthazar JT; Esposito DLA; Ayala JC; Schiefer A; Pfarr K; Hoerauf A; Alt S; Hesterkamp T; Grosse M; Stadler M; Golparian D; Unemo M; Read TD; Shafer WM
mSphere; 2022 Oct; 7(5):e0036222. PubMed ID: 36094073
[TBL] [Abstract][Full Text] [Related]
19. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine.
Gulati S; Shaughnessy J; Ram S; Rice PA
Front Immunol; 2019; 10():321. PubMed ID: 30873172
[TBL] [Abstract][Full Text] [Related]
20. In-silico Hierarchical Approach for the Identification of Potential Universal Vaccine Candidates (PUVCs) from Neisseria gonorrhoeae.
Jain R; Sonkar SC; Chaudhry U; Bala M; Saluja D
J Theor Biol; 2016 Dec; 410():36-43. PubMed ID: 27596531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
